According to this strategy, triple-negative breast cancer, c-erbB2 (+) breast cancers, inflammatory breast cancers, stage I or II ER (+)/HER2 (−) breast cancers, stage I c-erbB2 (+) breast cancers, and ER (+) patients with a DCIS were classified under level B. These patients were identified as those for whom treatment should begin before the end of the pandemic [9]. The gene discussed is ESR1; the disease is breast cancer.